- Home
- PSHG vs BOLD Comparison
PSHG vs BOLD Comparison
Compare PSHG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSHG | BOLD |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 25.7M |
| IPO Year | 2010 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PSHG | BOLD |
|---|---|---|
| Price | $2.34 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 138.7K | 64.6K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.34 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.96 |
| 52 Week High | $2.58 | $1.79 |
Technical Indicators
Market Signals| Indicator | PSHG | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 52.49 |
| Support Level | $1.77 | $1.15 |
| Resistance Level | $2.56 | $1.20 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 62.37 | 56.25 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.